Navigation Links
Rasheda Ali to Join Advisory Board of Brainstorm Cell Therapeutics
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- BrainStorm Cell Therapeutics Inc. (OTC Bulletin Board: BCLI), a leading developer of adult stem cell technologies and therapeutics, is excited and honored to state the appointment of Rasheda Ali, revered author and daughter of renowned boxer and long time Parkinson's sufferer Muhammad Ali, as a member of the company's Advisory Board. BrainStorm has announced results leading to a possible cure for Parkinson's, which drew the attention of philanthropist Ali, an advocate in finding a cure for her father's debilitating disease.

As the author of I'll Hold Your Hand So You Won't Fall - a Child's Guide to Parkinson's Disease her longtime goal has been to encourage a dialogue between parents and children. Continuing her efforts toward national and international awareness and pursuing medical breakthroughs for Parkinson's, she will now champion Brainstorm's research and advancements, in her new role.

"I am very excited to be part of the BrainStorm Advisory Board and focus more attention on spotlighting their groundbreaking research towards a cure for Parkinson's," says Ali. "This is obviously a very personal issue for me, as I continue to pray daily for a cure for my father, which it seems BrainStorm is determined to find. I cannot wait to lend a hand."

"As a role model and a living example of how to cope with her own father's struggle with Parkinson's, Rasheda is a natural fit for our cause. We are very excited to have her collaborate with BrainStorm as a pivotal member of our Advisory Board, joining the ranks of notable world class business leaders like Prof. Jacob Frenkel and Harvey Krueger," commented Chaim Lebovits, President. "We know through her passion to find a cure for her father, she will continue to do great things for those who suffer from Parkinson's -- both family and patient."

Leveraging her celebredom and humanitarian legacy, Rasheda wants to bring further awareness to the Parkinson's issue. Over 1 million Americans suffer from Parkinson's, with more victims, young and old, being diagnosed daily. 40% of victims are under the age of 60 and it is estimated that Parkinson's costs the U.S. over $26 billion annually in disability costs and lost productivity. Currently, there is no cure for Parkinson's though BrainStorm Cell Therapeutics is well on its way to conquering this horrible disease via adult stem cell research.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an early stage company engaged in developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology may have promise for treating several other diseases including MS and Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete the financings described in this press release and its ability to satisfy all of the closing conditions. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.

Contact: Alyssa Miller

(212) 584-4290; amiller@5wpr.com


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WHO lifts HongKong advisory
2. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
3. Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
4. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
5. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
6. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
7. LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
8. Study casts doubt on keyboard ills
9. Who Board To Discuss Asian Tsunami Related Health Issues
10. Abdominal Crunches Not The Best Option For Wash Board Abs.
11. Computer Keyboards In Hospitals Could Spread Infection To Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really ... cream can be incorporated into the post-surgical treatment plans of a variety of other ... dermaka cream is very effective for bruising and causes a rapid resolution of bruising ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and University ... Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate of ... she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
(Date:6/23/2016)... ... 23, 2016 , ... The U.S. Supreme Court decision on immigration has significant ... The Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would ... who worked in this country illegally, even though the newly - issued green cards ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: